EGR2

Across TCGA pan-cancer cohorts, EGR2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of EGR2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where EGR2 RNA is repressed in tumor relative to normal tissue. In most cancer types EGR2 is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

BLCA, THCA, and KICH are the cancer types where EGR2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EGR2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	IV	−2.204	<.001	11	view →
THCA	All	II,III,IV	−2.483	<.001	10	view →
KICH	Female	III,IV	−4.776	<.001	9	view →
LIHC	All	III,IV	−1.519	<.001	9	view →
UCEC	All	III,IV	−2.270	<.001	8	view →
LUAD	Female	All	−1.649	<.001	8	view →
KIRP	All	All	−1.460	<.001	7	view →
BRCA	All	III,IV	−2.085	<.001	6	view →
LUSC	Female	All	−1.435	<.001	6	view →
STAD	Male	II,III,IV	+0.974	.018	2	view →
KIRC	All	II,III,IV	−0.778	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

EGR2–BLCA

Open the BLCA breakdown →